Mesothelioma Treatment - Chemotherapy - Onconase
Onconase, which is also known as P-30 protein, is a derivative of eggs and early embryos of the leopard frog. Onconase has been proven to provide activity against many tumor cell lines, such as those produced by the asbestos-caused cancer, mesothelioma.
The clinical trial of Onconase was conducted at Columbia University. Dr. Taub, the trial's coordinator, did a two-phase study involving 105 patients who had advanced metastasizing mesothelioma. Onconase was given by IV to the patients for over 30 minutes each week.
The median survival time for these patients was nearly six months, and some patients achieved one- and two-year survival rates. These results were quite encouraging and prompted a Phase III trial of Onconase, conducted versus doxorubicin in patients who had unresectable mesothelioma. The survival times were similar in the two groups of Onconase trials, as well as for the trial of doxorubicin. However, the results in the test trials of Onconase versus doxorubicin favored Onconase.
The Treatment of Mesothelioma with Onconase
Onconase is one of the first embryonic stem cell products to reach the final stages of testing, currently in Phase IIIB trials. The drug shows much promise and may be considered as a potential early first-line preventative treatment for mesothelioma, which could mean prolonged life for those exposed to asbestos as mesothelioma is generally not diagnosed until its reached Stage III or IV.
Currently, the only way to receive this chemotherapy drug is through enrollment in one of these trials. Ask you doctor if you might be a candidate for Onconase clinical trials.
- Early Detection of Mesothelioma Crucial
2008-04-28 13:30:11
When Brandon Benoit suffered a football injury last year, he never dreamed that getting treated for that injury could change his life—and perhaps save it. When Benoit was treated for his injuries ... [read more] - Could Caffeine Help Treat Mesothelioma?
2008-04-24 16:46:33
A mesothelioma research group has discovered that treatment with anti-cancer drug Pemetrexed may be more effective if patients are treated with caffeine before r ... [read more] - Mesothelioma Researchers to Receive Innovator Award
2008-04-24 16:44:14
The Kirk A. and Dorothy P. Landon Foundation, in conjunction with the American Association for Cancer Research (AACR), has created two new funding opportunities for scientists working on cancer resear ... [read more]
